Impressive…

Here is a blog I wrote about why I feel MRD negativity should be used as a surrogate endpoint in #myeloma clinical trials. MRD as a Clinical Trial Endpoint: A Patient Perspective healthtree.org/myeloma/commun… #MMSM

« Un matin, après tant de désespoirs, une irrépressible envie de vivre nous annoncera que tout est fini et que la souffrance n'a pas plus de sens que le bonheur. »
Albert Camus

I’m not a MM specialist but I think this is huge!

While reviewing a paper, noticed this author's affiliation..
Looking forward for a membership's invitation...

📢¿Quieres formar parte de nuestro Servicio Hematologia - Hospital Universitari Vall d'Hebron🩸?
Ofrecemos un contrato para Facultativ@ Junior en la Unidad de CAR-T🔬
Programa fellow con posibilidad de ampliación

Incorporación inmediata!
El equipo CAR-T te espera!🧑‍⚕️DM para más información 📩 Vall d'Hebron Vall d’Hebron Institute of Oncology (VHIO)

Towards standardization of RWE studies. Much needed article

ascopubs.org/doi/10.1200/JC…

Not a transplanter but is is always delightful to read an expert in the field

nature.com/articles/s4140…

#AMA does not know how teams work and the scope of health professionals… do they see patients?

Sad news…one of the greatest

Low cost cell therapy…great summary of a potential treatment option

nature.com/articles/s4158…

RIP

Remembering the legendary Mário Zagallo – the only man to win the FIFA World Cup on four occasions ❤️

This is fascinating!

Thank you American Board of Internal Medicine (ABIM) for letting me know I passed the 10-y Onc Board 1 hour before oral presentation at #ASH23 #Cart

US healthcare system as its best…i wonder how lymphoma specific survival would look like. Interesting analysis

ash.confex.com/ash/2023/webpr…

Post CART relapse prognostic index- interesting tool

ash.confex.com/ash/2023/webpr…

NexCAR19, developed in India

This is an extremely important case report. Wonder why it is “publication only” at #ASH23

Risk of CMV reactivation in CART. Highest risk with steroids > 3d and BCMA CAR

academic.oup.com/cid/advance-ar…